{
    "clinical_study": {
        "@rank": "168224", 
        "arm_group": [
            {
                "arm_group_label": "Arm A1", 
                "arm_group_type": "Experimental", 
                "description": "Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999"
            }, 
            {
                "arm_group_label": "Arm A2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo"
            }, 
            {
                "arm_group_label": "Arm B1", 
                "arm_group_type": "Experimental", 
                "description": "Part B of study to assess effects of PF-05180999 on histamine-induced wheal"
            }, 
            {
                "arm_group_label": "Arm B2", 
                "arm_group_type": "Experimental", 
                "description": "Part B of study to assess effects of PF-05180999 on histamine-induced wheal"
            }, 
            {
                "arm_group_label": "Arm B3", 
                "arm_group_type": "Experimental", 
                "description": "Positive control to ensure histamine-induced wheal assay integrity"
            }, 
            {
                "arm_group_label": "Arm B4", 
                "arm_group_type": "Experimental", 
                "description": "Placebo control"
            }
        ], 
        "brief_summary": {
            "textblock": "PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce\n      vascular permeability.  The purpose of this study is to evaluate the safety, tolerability,\n      pharmacokinetics, and effects on histamine-induced wheal of single doses of PF-05180999 in\n      healthy adult subjects. Histamine-induced wheals are biomarkers of vascular permeability."
        }, 
        "brief_title": "A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects between the ages of 18 and 55 years\n\n          -  No history of clinically-relevant atopic or dermatological disease\n\n          -  Positive reaction to intradermal injection of histamine\n\n        Exclusion Criteria:\n\n          -  Subjects with screening laboratory test results that  deviate from the upper and/or\n             lower limits of the reference or acceptable range. The exception is that all liver\n             function tests must not exceed the upper limit of normal.\n\n          -  Subjects with evidence of, or history of, hepatic disorder, including acute or\n             chronic hepatitis B or hepatitis C\n\n          -  Intolerance to intradermal histamine injection.\n\n          -  Subjects with dark skin (Part B only)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981499", 
            "org_study_id": "B3441009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A1", 
                "description": "Ascending single oral doses of 120, 240, and 420 mg modified-release tablets", 
                "intervention_name": "PF-05180999", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm A2", 
                "description": "Placebo tablets", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B1", 
                "description": "Single 120 mg dose administered as modified release formulation", 
                "intervention_name": "120 mg MR PF-05180999", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B2", 
                "description": "Single 360 mg dose administered as modified release formulation", 
                "intervention_name": "360 mg MR PF-05180999", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B3", 
                "description": "Single 10 mg dose of cetirizine", 
                "intervention_name": "10 mg cetirizine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B4", 
                "description": "Placebo tablets", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Histamine", 
                "Histamine phosphate", 
                "Cetirizine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PF-05180999", 
            "safety", 
            "tolerability", 
            "pharmacokinetics", 
            "histamine", 
            "wheal", 
            "flare", 
            "migraine", 
            "PDE2"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3441009&StudyName=A%20Study%20of%20the%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%2C%20And%20Effects%20On%20Histamine-Induced%20Wheal%20Of%20PF-05180999%20In%20Healthy%20Adults%20%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Paul", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55114"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Maximum observed plasma concentration", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours post-dose"
            }, 
            {
                "description": "Time when Cmax occurred", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours post-dose"
            }, 
            {
                "description": "Measure of drug absorption and drug exposure", 
                "measure": "Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours post-dose"
            }, 
            {
                "description": "Measure of drug absorption and drug exposure", 
                "measure": "Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "0-infinity hours post-dose"
            }, 
            {
                "description": "Time for the plasma concentration to decrease by one-half.", 
                "measure": "Plasma Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours post-dose"
            }, 
            {
                "description": "Measure of drug effect", 
                "measure": "Area Under the Effect Curve (AUEC) for Histamine-Induced Wheal", 
                "safety_issue": "No", 
                "time_frame": "2-12 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981499"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measures of drug effect", 
                "measure": "Dose-response, exposure-response, and maximum response for PF-05180999 against histamine-induced wheal", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours post-dose"
            }, 
            {
                "description": "Measures of drug effect", 
                "measure": "Area Under the Effect Curve (AUEC) for histamine-induced flare; Dose-response, exposure-response, and maximum response for PF-05180999 against histamine-induced flare", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours post-dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "The trial was prematurely terminated on 01April2014 due to safety concerns."
    }
}